On-demand manufacturing of clinical-quality biopharmaceuticals.
Ontology highlight
ABSTRACT: Conventional manufacturing of protein biopharmaceuticals in centralized, large-scale, single-product facilities is not well-suited to the agile production of drugs for small patient populations or individuals. Previous solutions for small-scale manufacturing are limited in both process reproducibility and product quality, owing to their complicated means of protein expression and purification. We describe an automated, benchtop, multiproduct manufacturing system, called Integrated Scalable Cyto-Technology (InSCyT), for the end-to-end production of hundreds to thousands of doses of clinical-quality protein biologics in about 3 d. Unlike previous systems, InSCyT includes fully integrated modules for sustained production, efficient purification without the use of affinity tags, and formulatio
SUBMITTER: Crowell LE
PROVIDER: S-EPMC6443493 | biostudies-literature | 2018 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA